The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Sandostatin LAR 20 mg powder and solvent for suspension for injection

Novartis Ireland LimitedPA0896/028/005

Main Information

Trade NameSandostatin LAR 20 mg powder and solvent for suspension for injection
Active SubstancesOctreotide
Dosage FormPowder and solvent for suspension for injection
Licence HolderNovartis Ireland Limited
Licence NumberPA0896/028/005

Group Information

ATC CodeH01CB Somatostatin and analogues
H01CB02 octreotide


License statusAuthorised
Licence Issued13/07/1998
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back